Cargando…

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

The purpose of this study was to examine the association between the leucocyte nadir and prognosis in breast cancer patients receiving adjuvant chemotherapy consisting of cyclophosphamide, methotrexate and fluorouracil (CMF). Three hundred and sixty-eight patients with node-positive breast cancer wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poikonen, P, Saarto, T, Lundin, J, Joensuu, H, Blomqvist, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363113/ https://www.ncbi.nlm.nih.gov/pubmed/10468293 http://dx.doi.org/10.1038/sj.bjc.6690594

Ejemplares similares

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
por: Erselcan, T, et al.
Publicado: (2000)

The leucocyte nadir, a predictor of chemotherapy efficacy?
por: Kvinnsland, S
Publicado: (1999)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.
por: Saarto, T., et al.
Publicado: (1997)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Adjuvant chemotherapy for colon carcinoma with positive lymph nodes: use and benefit in routine health care practice
por: Bouchardy, C, et al.
Publicado: (2001)

Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
por: Cameron, D A, et al.
Publicado: (2003)

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
por: De Placido, S., et al.
Publicado: (1995)

Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy
por: Joly, F, et al.
Publicado: (2000)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
por: Saarto, T., et al.
Publicado: (1997)

Low CD4 nadir linked to widespread cortical thinning in adults living with HIV
por: Hassanzadeh-Behbahani, Shiva, et al.
Publicado: (2019)

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast
por: Harper-Wynne, C, et al.
Publicado: (1999)

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
por: Colleoni, M, et al.
Publicado: (2002)

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
por: Yu, Ke-Da, et al.
Publicado: (2013)

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience
por: De Maio, Ermelinda, et al.
Publicado: (2005)

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
por: Saarto, T, et al.
Publicado: (2001)

Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
por: Poikonen, P, et al.
Publicado: (2005)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
por: Earl, H M, et al.
Publicado: (2012)

Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

CMF, Chaikin money flow: changes anticipating price reversal
por: Thomsett, Michael C
Publicado: (2011)

Oxidation of 5-Chloromethylfurfural (CMF) to 2,5-Diformylfuran (DFF)
por: Vicente, Ana I., et al.
Publicado: (2017)

AO Craniomaxillofacial Surgery (AO CMF): A World of Opportunities
por: Kadam, Dinesh
Publicado: (2020)

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.
por: Fraser, S. C., et al.
Publicado: (1993)

Induction of interferon synthesis in rainbow trout leucocytes by various homeotherm viruses
por: Snegaroff, J.
Publicado: (1993)

Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy
por: Boström, Peter J., et al.
Publicado: (2016)

Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids
por: Vehmanen, L, et al.
Publicado: (2004)

Long-term survival in node-positive breast cancer treated by locoregional therapy alone.
por: Joensuu, H., et al.
Publicado: (1998)

Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer
por: Tominaga, Tetsuro, et al.
Publicado: (2016)

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001)

A graphical LASSO analysis of global quality of life, sub scales of the EORTC QLQ-C30 instrument and depression in early breast cancer
por: Poikonen-Saksela, Paula, et al.
Publicado: (2022)

Reaching the Nadir of Medication Overuse in Chronic Migraine
por: Onan, Dilara, et al.
Publicado: (2022)

EXPERIMENTAL STUDY OF CHEMOTHERAPY RELATED LEUKOCYTOPENIA TREATED BY VARIOUS PEROAL LEUCOCYTE INCREASING DRUGS
por: Xiping, Zhang, et al.
Publicado: (2016)

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
por: O'Byrne, K. J., et al.
Publicado: (1998)

Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer.
por: Miles, D. W., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_oqq1ga5d83pp1unmabab8o8pmf